Radiation Segmentectomy for Hepatocellular Carcinoma

Muhamad Serhal, Farnaz Dadrass, Edward Kim, Robert J. Lewandowski

Research output: Contribution to journalReview articlepeer-review

Abstract

The application of trans-arterial radioembolization (TARE) with Yttrium-90, historically a palliative treatment option for patients with advanced hepatocellular carcinoma (HCC), is evolving. Radiation segmentectomy (RADSEG), the segmental delivery of an ablative radiation dose, is a treatment option for patients with earlier-stage HCC. This review presents an in-depth exploration of RADSEG, emphasizing its technical considerations, dosimetry advancements, and patient selection. The integration of RADSEG into the Barcelona Clinic Liver Cancer (BCLC) paradigm will be highlighted. RADSEG outcomes concerning safety and efficacy will be explored and compared with traditional locoregional cancer treatments like trans-arterial chemoembolization (TACE), percutaneous thermal ablation, and surgical resection, with an eye on future directions and considerations.

Original languageEnglish
Pages (from-to)617-628
Number of pages12
JournalCurrent Oncology
Volume31
Issue number2
DOIs
StatePublished - Feb 2024
Externally publishedYes

Keywords

  • Barcelona Clinic Liver Cancer paradigm
  • hepatocellular carcinoma
  • radiation segmentectomy
  • radioembolization

Fingerprint

Dive into the research topics of 'Radiation Segmentectomy for Hepatocellular Carcinoma'. Together they form a unique fingerprint.

Cite this